HUTCHMED  DRC share price logo

HUTCHMED DRC

NASDAQ: HCM

Mid Cap

$13.24

-0.20

(-1.49%)

as on

HUTCHMED DRC Stock Performance

as on May 2, 2026 at 6:57 am IST

  • Day's Low

    Day's High

    $12.82
    $13.50
    downward going graph

    3.17%

    Downside

    1.96%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $12.82
    $19.50
    downward going graph

    3.17%

    Downside

    47.28%

    Upside

    downward going graph

HUTCHMED DRC share price movements today

Previous Close
$13.44
Open
$13.50
Volume
276.9K
Day's Low - High
$12.82 - $13.50
52 Week Low - High
$12.82 - $19.50

HUTCHMED DRC Historical Returns

1 Month Return
-13.75 %
3 Month Return
-8.65 %
1 Year Return
-11.33 %
3 Year Return
-7.45 %
5 Year Return
-52.99 %

HUTCHMED DRC Stock Fundamentals & Key Indicators

Check HUTCHMED DRC market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.3B

EPS (TTM)

0.3841

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.98%

PE Ratio (TTM)

5.07

Industry PE ratio

20.393846153846155

PEG Ratio

0

EBITDA

-25.9M

Revenue (TTM)

548.5M

Profit Margin

83.30%

Return On Equity TTM

45.25%

HUTCHMED DRC Stock Valuation

Track how HUTCHMED DRC P/E has moved over time to understand its valuation trends.

HUTCHMED DRC in the last 5 years

  • Overview

  • Trends

Lowest (-42.82x)

September 30, 2021

Today (5.07x)

May 2, 2026

Industry (20.39x)

May 2, 2026

Highest (67.34x)

December 31, 2023

LowHigh

Today’s Price to Earnings Ratio: 5.07x

HUTCHMED DRC vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of HUTCHMED DRC with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$2.3B-52.99%5.0783.30%
BUY$24.2BNA20.4641.94%
HOLD$17.4B13.08%NA-24.58%
BUY$41.7BNA18.7615.11%
BUY$48.2B-34.02%18.9628.24%

Stock Returns calculator for HUTCHMED DRC Stock including INR - Dollar returns

The HUTCHMED DRC stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

HUTCHMED DRC investment value today

Current value as on today

₹99,382

Returns

-₹618

(-0.62%)

Returns from HUTCHMED DRC Stock

-₹11,733 (-11.73%)

Dollar Impact

₹11,116 (+11.12%)

Analyst Recommendation on HUTCHMED DRC Stock

Based on 22 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 22 analysts, 90.91% of analysts recommend a 'BUY' rating for HUTCHMED DRC. Average target price of $22.85

HUTCHMED DRC Share Price Target

Get share price movements and forecasts by analysts on HUTCHMED DRC.

What analysts predicted

42.06%UPSIDE

Target Price

$22.85

Current Price

$13.24

Analyzed by

22 Analysts

Target

$22.85

HUTCHMED DRC target price $22.85, a slight upside of 42.06% compared to current price of $13.24. According to 22 analysts rating.

HUTCHMED DRC Stock’s Investor Sentiment and Interest

Search interest for HUTCHMED DRC Stock has increased by 55% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:55% versus previous 30 day period

HUTCHMED DRC Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
266
266
152
152
152
152
162
162
138
138
Gross Profit
162
162
-86
143
62
62
-28
-28
55
55
Operating Income
55
55
-46
-46
-13
-13
-8
-8
-1
-1
EBITDA
57
57
-44
-44
-10
-10
-5
-5
1
1
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
86
86
-33
-33
14
14
8
8
259
259
Income Tax Expense
1
1
0
0
1
1
2
2
31
31
Net Income
84
84
-33
-33
12
12
5
5
227
227
Net Profit Margin
31.63%
31.63%
-22.21%
-22.21%
8.44%
8.44%
3.68%
3.68%
163.84%
163.84%

HUTCHMED DRC Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
216
241
214
204
227
356
426
837
630
549
Gross Profit
59
65
70
44
39
97
115
453
281
212
Operating Income
-46
-53
-92
-152
-198
-328
-409
18
-43
-54
EBITDA
-43
-49
-82
-135
-190
-207
-401
26
-31
-41
Interest Expense
1
1
1
1
0
0
0
0
2
2
Depreciation
-
2
3
4
6
7
8
8
12
13
Income Before Tax
18
-19
-67
-100
-110
-155
-360
105
45
522
Income Tax Expense
4
3
3
3
4
11
0
4
7
63
Net Income
11
-26
-74
-106
-125
-194
-360
100
37
458
Net Profit Margin
5.41%
-11.08%
-34.94%
-51.75%
-55.15%
-54.66%
-84.62%
12.03%
5.99%
83.30%

HUTCHMED DRC Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
84
-33
-33
12
12
5
5
227
227
Operating Cash Flow
113
-3
-3
-19
-19
20
20
-36
-36
Investing Cash Flow
-157
12
12
-2
-2
-45
-45
8
8
Financing Cash Flow
2
21
21
-16
-16
0
0
4
4
Change in Cash
-90
-192
60
-39
203
-203
-
-
-

HUTCHMED DRC Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-22
-71
-103
-115
-167
-360
100
37
458
Operating Cash Flow
-8
-32
-80
-62
-204
-268
219
0
-64
Investing Cash Flow
-260
43
119
-125
-306
296
-291
-96
-29
Financing Cash Flow
273
-8
-1
296
650
-82
48
-30
7
Change in Cash
5
0
35
114
141
-64
-29
-129
-82

Global Institutional Holdings in HUTCHMED DRC

Funds
Holdings
Renaissance Technologies Corp
0.08%
Bank of America Corp
0.01%
Tema ETFs
0.02%
Dimensional Fund Advisors, Inc.
0.03%
ABN AMRO Investment Solutions
0.04%

Insights on HUTCHMED DRC

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, 5.96M → 227.47M (in $), with an average increase of 48.7% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, United Therapeutics Corporation has given 164.4% return, outperforming this stock by 177.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, United Therapeutics Corporation has given 93.6% return, outperforming this stock by 104.9%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, HCM stock has moved down by -13.7%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 162.26M → 138.83M (in $), with an average decrease of 7.2% per quarter

About HUTCHMED DRC

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
OrganisationHUTCHMED DRC
HeadquartersCheung Kong Center, Hong Kong, Hong Kong
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Chig Fung Cheng BEc, CA
E-voting on sharesClick here to vote

Key Management of HUTCHMED DRC

Name

Title

Dr. Wei-Guo Su B.Sc., Ph.D.

CEO, Chief Scientific Officer & Executive Director (Leave of Absence)

Ms. Yiling Cui

Executive VP & Head of Operations

Dr. Xinhui Hu Ph.D.

Executive Vice President & Chief Technical Officer

Mr. David Ng

Head of Investor Relations & Capital Strategies

Mr. Chig Fung Cheng BEc, CA

Acting CEO, CFO & Executive Director

Mr. Charles George Rupert Nixon

Group General Counsel

Mr. Kin Hung Lee M.B.A.

Senior Vice President of Corporate Management & Communications

Ms. Selina Zhang

Senior Vice President of Global Human Resources

Dr. Qingmei Wang Ph.D.

Executive Vice President of Business Development & Strategic Alliances

Dr. Thomas Fu

Senior Vice President of Global Quality

FAQs

What is HUTCHMED DRC share price today?

HUTCHMED DRC share price today is $13.24 as on at the close of the market. HUTCHMED DRC share today touched a day high of $13.5 and a low of $12.82.

What is the 52 week high and 52 week low for HUTCHMED DRC share?

HUTCHMED DRC share touched a 52 week high of $19.5 on and a 52 week low of $12.82 on . HUTCHMED DRC stock price today i.e. is closed at $13.24,which is 32.10% down from its 52 week high and 3.28% up from its 52 week low.

What is HUTCHMED DRC's market capitalisation today?

HUTCHMED DRC market capitalisation is $0.00T as on .

How to invest in HUTCHMED DRC Stock (HCM) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for HUTCHMED DRC on INDmoney app. Click on Buy button. You can invest as low as $1.5 in HUTCHMED DRC Shares that will get you 0.1133 shares as per HUTCHMED DRC share price of $13.24 per share as on May 2, 2026 at 1:27 am IST.

What is the minimum amount required to buy HUTCHMED DRC Stock (HCM) from India?

Indian investors can start investing in HUTCHMED DRC (HCM) shares with as little as ₹94.91 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.10 in HUTCHMED DRC stock (as per the Rupee-Dollar exchange rate as on ). Based on HUTCHMED DRC share’s latest price of $13.24 as on May 2, 2026 at 1:27 am IST, you will get 0.7553 shares of HUTCHMED DRC. Learn more about fractional shares .

What are the returns that HUTCHMED DRC has given to Indian investors in the last 5 years?

HUTCHMED DRC stock has given -52.99% share price returns and 28.57% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?